Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Lessened by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 66.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,007 shares of the biopharmaceutical company’s stock after selling 68,109 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Amicus Therapeutics were worth $374,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics during the third quarter valued at $26,000. Hazlett Burt & Watson Inc. lifted its stake in Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. lifted its stake in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new position in shares of Amicus Therapeutics in the third quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics in the third quarter worth approximately $55,000.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $11.46, for a total value of $85,950.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 30,401 shares of company stock worth $339,363. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on FOLD. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Cantor Fitzgerald increased their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Guggenheim raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Stock Performance

FOLD stock opened at $9.90 on Tuesday. The firm has a 50 day moving average of $10.51 and a two-hundred day moving average of $10.62. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -29.12 and a beta of 0.60. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.